Shares of Danish pharmaceutical giant Novo Nordisk plummeted nearly 15% in Thursday's trading session, marking its worst day in over a decade. This sharp decline followed the release of its first-quarter 2024 financial results, which, while showing robust growth driven by its groundbreaking obesity drugs, failed to meet Wall Street's lofty expectations and raised concerns about the sustainability of its expansion pace. The market reaction underscores the volatility and high expectations surrounding leading companies in the lucrative weight-loss medication field, known as GLP-1 receptor agonists.
Novo Nordisk, globally known for its diabetes drug Ozempic, has seen its valuation skyrocket in recent years due to the unprecedented success of Wegovy, its version specifically approved for weight loss. First-quarter revenue grew 22% year-over-year, reaching 65.3 billion Danish kroner (approximately $9.4 billion), driven by a 41% increase in sales of its Obesity Care products. However, analysts had projected even higher figures, and the company maintained its full-year growth guidance, choosing not to raise it despite the strong performance. This decision, interpreted as a signal of caution, was a key driver of the massive sell-off.
The context is crucial. Novo Nordisk and its rival Eli Lilly have become the undisputed protagonists of a medical and market revolution, with demand far outstripping production capacity. "The results are solid in absolute terms, but the market had priced in a perfection that is difficult to maintain in an environment of limited capacity and growing competition," commented Lars Fruergaard Jørgensen, CEO of Novo Nordisk, in a call with analysts. The company acknowledged it continues to invest heavily to expand its manufacturing capacity, but bottlenecks in the supply chain for injection devices (pens) remain a significant operational challenge.
The impact of this drop extends beyond Denmark's borders. Novo Nordisk is Europe's most valuable company, and its performance carries considerable weight in key indices like the STOXX Europe 600. Thursday's correction wiped out tens of billions of euros in market capitalization, affecting investment funds and retail investors worldwide. Furthermore, it highlights the critical questions facing the sector: Can demand for these drugs, with their high prices and ongoing insurance coverage debates, be sustained long-term? How will the eventual entry of more competitors and generics affect the landscape?
For investors, the lesson is clear: even in explosively growing sectors, valuation and expectations must align with operational reality. Novo Nordisk's correction can be seen as a healthy reset after a meteoric rise, bringing its valuation closer to more sustainable fundamentals. In the long term, the business fundamentals remain robust, with a pipeline of innovative products and a global obesity and diabetes market that continues to expand. However, the episode serves as a reminder that in financial markets, sometimes even good performance is not enough when the extraordinary is expected. The company's future will depend on its ability to scale production, manage competition, and demonstrate the long-term benefits of its therapies beyond weight loss.